

Supplementary Tables

Table S1. Characteristics of patients with stage IE ENKTL.

Characteristic	Sequential Group (%)	Sandwich Group (%)	p	All n (%)
Gender			0.694	
Male	61 (68.5)	50 (71.4)		111 (69.8)
Female	28 (31.5)	20 (28.6)		48 (30.2)
Age			0.074	
>60	9 (10.1)	2 (2.9)		11 (6.9)
≤60	80 (89.9)	68 (97.1)		148 (93.1)
ECOG			0.864	
0–1	88 (98.9)	69 (98.6)		157 (98.7)
2–4	1 (1.1)	1 (1.4)		2 (1.3)
LDH			0.701	
Elevated	24 (27.0)	17 (24.3)		41 (25.8)
Normal	65 (73.0)	53 (75.7)		118 (74.2)
B symptoms			0.439	
Present	55 (61.8)	39 (55.7)		94 (59.1)
Absent	34 (38.2)	31 (44.3)		65 (40.9)
PINK			0.059	
Low-risk	77 (86.5)	64 (95.5)		141 (90.4)
Intermediate-risk	12 (13.5)	3 (4.5)		15 (9.6)
PINK-E			0.082	

Low-risk	38 (90.5)	30 (100.0)	68 (94.4)
Intermediate-risk	4 (9.5)	0 (0.0)	4 (5.6)
Local invasiveness			0.269
Present	46 (51.7)	30 (42.9)	76 (47.8)
Absent	43 (48.3)	40 (57.1)	83 (52.2)
Chemotherapy regimen			0.494
GELOX	69 (77.5)	57 (81.4)	126 (79.2)
SMILE	8 (9.0)	7 (10.0)	15 (9.5)
VLP	12 (13.5)	6 (8.6)	18 (11.3)

Table S2. Characteristics of patients with stage IIE ENKTL.

Characteristic	Sequential Group (%)	Sandwich Group (%)	p	All n (%)
Gender			0.363	
Male	19 (86.4)	26 (76.5)		45 (80.4)
Female	3 (13.6)	8 (23.5)		11 (19.6)
Age			0.301	
>60	4 (18.2)	3 (8.8)		7 (12.5)
≤60	18 (81.8)	31 (91.2)		49 (87.5)
ECOG			0.417	
0–1	22 (100.0)	33 (97.1)		55 (98.2)
2–4	0 (0.0)	1 (2.9)		1 (1.8)
LDH			0.947	
Elevated	6 (27.3)	9 (26.5)		15 (26.8)
Normal	16 (72.7)	25 (73.5)		41 (73.2)
B symptoms			0.514	
Present	13 (59.1)	23 (67.6)		36 (64.3)
Absent	9 (40.9)	11 (32.4)		20 (35.7)
PINK			0.660	
Low-risk	17 (77.3)	32 (86.5)		49 (83.1)
Intermediate-risk	4 (18.2)	4 (10.8)		8 (13.5)
High-risk	1 (4.5)	1 (2.7)		2 (3.4)
PINK-E			0.215	

Low-risk	7 (100.0)	12 (80.0)	19 (86.4)
Intermediate-risk	0 (0.0)	2 (13.3)	2 (9.1)
High-risk	0 (0.0)	1 (6.7)	1 (4.5)
Local invasiveness			0.397
Present	16 (72.7)	21 (61.8)	37 (66.1)
Absent	6 (27.3)	13 (38.2)	19 (33.9)
Chemotherapy regimen			0.665
GELOX	15 (68.2)	25 (73.5)	40 (71.4)
SMILE	3 (13.6)	4 (11.8)	7 (12.5)
VLP	4 (18.2)	5 (14.7)	9 (16.1)

Table S3. Characteristics of patients with ENKTL, who received sequential chemoradiotherapy.

Characteristic	RT+CT group (%)	CT+RT group (%)	p	All n (%)
Gender			0.409	
Male	22 (66.7)	58 (74.4)		80 (72.1)
Female	11 (33.3)	20 (25.6)		31 (27.9)
Age			0.228	
>60	2 (6.1)	11 (14.1)		13 (11.7)
≤60	31 (93.9)	67 (85.9)		98 (88.3)
ECOG			0.514	
0–1	33 (100.0)	77 (98.7)		110 (99.1)
2–4	0 (0.0)	1 (1.3)		1 (0.9)
Ann Arbor stage			0.186	
IE	29 (87.9)	60 (76.9)		89 (80.2)
IIE	4 (12.1)	18 (23.1)		22 (19.8)
LDH			0.370	
Elevated	7 (21.2)	23 (29.5)		30 (27.0)
Normal	26 (78.8)	55 (70.5)		81 (73.0)
B symptoms			0.604	
Present	19 (57.6)	49 (62.8)		68 (61.3)
Absent	14 (42.4)	29 (37.2)		43 (38.7)
PINK			0.591	

Low-risk	29 (87.9)	65 (83.3)	94 (84.7)
Intermediate-risk	3 (9.1)	13 (16.7)	16 (14.4)
High-risk	1 (3.0)	0 (0.0)	1 (0.9)
PINK-E			0.291
Low-risk	10 (100.0)	35 (89.7)	45 (91.8)
Intermediate-risk	0 (0.0)	4 (10.3)	4 (8.2)
Local invasiveness			0.151
Present	15 (45.5)	47 (60.3)	62 (55.9)
Absent	18 (54.5)	31 (39.7)	49 (44.1)
Chemotherapy regimen			0.986
GELOX	25 (75.8)	59 (75.6)	84 (75.7)
SMILE	3 (9.1)	8 (10.3)	11 (9.9)
VLP	5 (15.1)	11 (14.1)	16 (14.4)